Conditions: Hyperlipoproteinemia Type II Hypercholesterolemia, Familial
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 306
Healthy volunteers: no

Brief summary:
The objective of this study is to evaluate the efficacy and tolerability of adding anacetrapib to ongoing statin therapy in participants with heterozygous familial hypercholesterolemia (HeFH).

Detailed description:

Arms:
arm 1: Participants were administered one tablet of 100 mg anacetrapib orally once daily with a meal for 52 weeks during the treatment period. arm 2: Participants were administered one matching placebo tablet orally once daily with a meal for 52 weeks during the treatment period.

Interventions: intervention 1: Anacetrapib intervention 2: Placebo
Intervention descriptions: intervention 1: One oral tablet, orally once daily for 52 weeks intervention 2: One oral tablet once daily for 52 weeks

Protocol document: